There have been many articles over the weekend containing misinformation about EMA’s scientific considerations regarding AstraZeneca’s COVID-19 vaccine.
EMA’s regulatory position in respect to this vaccine is clear: the benefit-risk balance is positive and the vaccine remains authorised in all populations.
The source of the misinformation was an article published in an Italian newspaper, which misquoted one of our experts. The article has been revised since and we have also asked for a formal correction.
Many news organisations have published articles on the basis of the original, incorrect interview.
In the interest of correct and fact-based reporting, we are asking you to update articles containing false information to reflect EMA’s unchanged regulatory position vis-à-vis AstraZeneca’s Vaxzevria.
If recommendations change, EMA will communicate this in a transparent, pro-active way to the media and the public and journalists are encouraged to check our website for any new information.
ema.europa.eu
